OptimizeRx (NASDAQ:OPRX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 22.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $19.69 million which beat the analyst consensus estimate of $18.13 million by 8.60 percent. This is a 51.43 percent increase over sales of $13.00 million the same period last year.
OptimizeRx Q1 Adj $(0.11) Beats $(0.13) Estimate, Sales $19.69M Beat $18.13M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.